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Abstract
Background: Fc gamma receptors (FccRs) play a crucial role in immunity by linking IgG antibody-mediated responses with
cellular effector and regulatory functions. Genetic variants in these receptors have been previously identified as risk factors
for several chronic inflammatory conditions. The present study aimed to investigate the presence of copy number variations
(CNVs) in the FCGR3B gene and its potential association with the autoimmune disease rheumatoid arthritis (RA).
Methodology/Principal Findings: CNV of the FCGR3B gene was studied using Multiplex Ligation Dependent Probe
Amplification (MLPA) in 518 Dutch RA patients and 304 healthy controls. Surprisingly, three independent MLPA probes
targeting the FCGR3B promoter measured different CNV frequencies, with probe#1 and #2 measuring 0 to 5 gene copies
and probe#3 showing little evidence of CNV. Quantitative-PCR correlated with the copy number results from MLPA
probe#2, which detected low copy number (1 copy) in 6.7% and high copy number ($3 copies) in 9.4% of the control
population. No significant difference was observed between RA patients and the healthy controls, neither in the low copy
nor the high copy number groups (p-values=0.36 and 0.71, respectively). Sequencing of the FCGR3B promoter region
revealed an insertion/deletion (indel) that explained the disparate CNV results of MLPA probe#1. Finally, a non-significant
trend was found between the novel -256A.TG indel and RA (40.7% in healthy controls versus 35.9% in RA patients;
P=0.08).
Conclusions/Significance: The current study highlights the complexity and poor characterization of the FCGR3B gene
sequence, indicating that the design and interpretation of genotyping assays based on specific probe sequences must be
performed with caution. Nonetheless, we confirmed the presence of CNV and identified novel polymorphisms in the
FCGR3B gene in the Dutch population. Although no association was found between RA and FCGR3B CNV, the possible
protective effect of the -256A.TG indel polymorphism must be addressed in larger studies.
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Introduction
Fc receptors are proteins expressed on the surface of immune
cells, whose function is to help in the recognition and elimination
of invading pathogens [1]. Fc receptors bind to antibodies
attached on the surface of pathogens or infected cells, triggering
immune effector responses, such as phagocytosis, antibody-
dependent cellular cytotoxicity, cytokine release and antigen
presentation. There are Fc receptors for each immunoglobulin
(Ig) class: FcaR, FcdR, FceR, FccR and FcmR, for IgA, IgD, IgE,
IgG and IgM, respectively. IgG antibodies are the most abundant
serum immunoglobulins, are predominantly involved in the
secondary immune response and increased amounts can occur
upon infection, chronic inflammation and autoimmune diseases.
Therefore, FccRs are thought to play a crucial role in immunity,
as well as in the pathogenesis of several autoimmune diseases,
including rheumatoid arthritis (RA) [2]. FccRs vary in their
cellular distribution and affinity for different IgG isotypes and can
be divided in three general classes: FccRI (isoforms FccRIA, IB
and IC), FccRII (isoforms FccRIIA, IIB and IIC) and FccRIII
(isoforms FccRIIIA and IIIB). These include activatory receptors,
such as FccRI, FccRIIA and FccRIIIA, and the inhibitory
receptor FccRIIB [3]. Furthermore, FccRs can be distinguished
between high-affinity receptors (FccRI) and low-affinity receptors
(FccRII and FccRIII). These low-affinity receptors are encoded by
highly homologous FCGR genes, located in a genetically complex
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believed that the different FCGR genes in this locus are the result of
multiple duplication and recombination events during evolution
[5]. Additionally, this region displays extensive genetic variation,
which has been associated with susceptibility to various chronic
inflammatory disorders [6–8]. In particular, single nucleotide
Figure 1. Genomic organization of the human FCGR locus in the chromosome 1q23.3. A. FCGR2A, FCGR2B, FCGR2C, FCGR3A and FCGR3B
are drawn in different shades of gray, representing the regions of homology between the genes. Arrows mark the direction of transcription. MLPA
probes designed to measure FCGR3B copy number are located in the promoter region (zoom). B. Zoom of the promoter sequence of FCGR3B aligned
against the homologous FCGR3A gene. The first exon of FCGR3B is highlighted in grey, MLPA probes in blue, quantitative PCR and sequencing
primers in green. Red arrows mark the ligation site of the MLPA probes, which target paralogous sequence variations between the FCGR3A and
FCGR3B genes to assure specificity.
doi:10.1371/journal.pone.0013173.g001
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FCGR3A (V158F) and FCGR3B (NA1/NA2), have been reported
in association with systemic lupus erythematosus (SLE), rheuma-
toid arthritis (RA) and/or idiopathic thrombocytopenia purpura
(ITP) [9–17].
Although less studied than SNPs, copy number variants (CNVs)
are also important sources of genetic variation. A CNV is defined
as a sequence of DNA .1 kb that is present in altered copy
number when compared with a reference genome [18]. Several
recent studies have demonstrated that some genes or groups of
genes can show variation in copy number [19–24]. In total, copy
number variable regions may cover as much as 12% of the human
genome, many of which exist with relatively high frequency (.5%)
in general human populations and are also present at orthologous
loci in other species [18,20,25]. The first evidence that copy-
number alterations can influence human phenotypes came from
sporadic diseases, termed ‘genomic disorders’, caused by de novo
structural alterations [26]. The number of genomic disorders has
grown, with several dozen reported to date [27]. In addition to
such sporadic diseases, inherited CNVs have been found to
underlie Mendelian diseases in several families [28–30]. Nonethe-
less, CNVs have been implicated in only a few percent of the 2,000
or more Mendelian diseases so far explained at a molecular level.
Little is known about the genetic basis of common, complex
phenotypes, and it is premature to predict the relative proportion
of complex disease explained by SNPs and CNVs. In principle,
complex disease might be more susceptible to ‘soft’ forms of
variation such as variation in non-coding sequences or copy
number which alter gene dose without abolishing gene function.
Common CNVs have been reported to be associated with several
complex disease phenotypes including HIV acquisition and
progression [31–33]. Furthermore, CNVs have been implicated
in several autoimmune diseases. For example, lower CN of
FCGR3B and complement component C4 genes have been
associated with SLE susceptibility [32–35]. Higher CN of CCL3L1
has been suggested as a risk factor for developing RA [36].
Additionally, CNV of FCGR3B was associated with microscopic
polyangiitis and Wegener’s granulomatosis [35].
Given the important role of FccRs in immunity, we are
interested in whether genetic variation in these genes associates
with susceptibility to rheumatoid arthritis (RA). In a previous
study, we showed that FCGR3A 158V/V genotype but not CNV
conferred risk to anti-citrullinated peptide antibodies (ACPA)
positive RA [37]. In the present report, we focused on the FCGR3B
gene.
Materials and Methods
Patients and healthy controls
Patients were 518 Dutch Caucasian individuals with RA who
fulfilled the American College of Rheumatology (ACR) classifica-
tion criteria for RA, as described elsewhere [38,39]. Controls were
304 unrelated healthy Dutch Caucasians with no history of RA
[40]. An informed written consent according to the Declaration of
Helsinki was obtained for both patients and controls. The Leiden
institutional review board, Commissie Medische Ethiek, approved
all protocols. Anti-cyclic citrullinated peptide antibodies (ACPA)
were positive in 59.6% of RA patients and was tested using
Immunoscan CCPlus (CCP2 Euro-Diagnostica, Arnhem, the
Netherlands).
Multiplex ligation-dependent probe amplification
Copy number variation (CNV) of the FCGR3B gene was
assessed using Multiplex Ligation-dependent Probe Amplification
(MLPA), which is a sensitive method for copy number quantifi-
cation [41]. MLPA probe design and assay were performed as
described by White et al. [42,43]. Due to the very high homology
in nucleotide sequences of FCGRs genes, the choices for
appropriate MLPA probes were limited. Three probe pairs were
designed for FCGR3B, which locate to the promoter region of the
gene, based on sequence information from NCBI build 36.1 and
dbSNP built 126. The MLPA probe sequences used are shown in
Table 1. Three genes CREBBP, EXT1 and EP300 were used as
control genes in each assay. The MLPA results were analyzed as
described by White et al. [42]. The height of each probe specific
peak was divided by the sum of three control peaks (from
CREBBP, EXT1 and EP300), to calculate the sample to control
ratio. For each target gene, the normalized ratio was calculated by
setting the median ratio across all samples within an assay at the
value of 2. The normalized ratio for each individual was calculated
and plotted (Figure 2). Subgroups corresponding to different gene
copy numbers were defined by eye and confirmed by cluster
analysis (using R statistical software version 2.5.0), and are
delineated by elliptical lines.
Table 1. MLPA probes sequences used for CNV typing of FCGR3B and control genes.
Probe_ _Orientation Sequence
FCGR3B#1_Forward CGTGGAGATAATATTGAGGCAGAGACACTGCTAGTGGTCA
FCGR3B#1_Reverse AAGATTTGAAAGGACAACTTTCTGTGTGCAGGCAGGGC
FCGR3B#2_Forward CCGACGTACGTATCTAAATCCAGGAGATGGGGGCAAGCATCCTGGGAA
FCGR3B#2_Reverse AGCTGAGGGCACACTCTGGCAGATTCTGTGTG
FCGR3B#3_Forward CCCCACCTTGCCTCCAGGCTCTTTCCTTCCTA
FCGR3B#3_Reverse TTCCTGTTCTATGGTGGGGCTCCATTGCGAGA
CREBBP_Forward CCAGCTAGTGGAATTCAAAACACAATTGGTTCTGTTGGCACA
CREBBP_Reverse GGGCAACAGAATGCCACTTCTTTAAGTAACCC
EP300_Forward CCAACCTAAGCACTGTTAGTCAGATTGATCCCAGCTCCAT
EP300_Reverse AGAAAGAGCCTATGCAGCTCTTGGACTACCCTATCA
EXT1_Forward CCTGAAGAACATGGTGGACCAATTGGCCAATTGTGAGGACAT
EXT1_Reverse TCTCATGAACTTCCTGGTGTCTGCTGTGACAAAATTGCCTC
doi:10.1371/journal.pone.0013173.t001
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To verify the results of the different MLPA probes for FCGR3B
gene, a quantitative PCR (qPCR) assay was designed based on
primers located within the promoter region of FCGR3B gene, the
same regions where the MLPA probes for FCGR3B were located.
24 samples showing different copy numbers of FCGR3B in the
MLPA assay were analysed by qPCR. Sequences of the primers
used were, FCGRIIIB_qPCR_FW (CAA GCA TCC TGG GAA
AGC T), FCGRIIIB_qPCR_RV (TAC TCT CCC AAA GGT
CTG C), FOXP2_FW (TGA CAT GCC AGC TTA TCT GTT
T) and FOXP2_RV (GAG AAA AGC AAT TTT CAC AGT
CC). Quantitative PCR was conducted in triplicate on 25 ng
genomic DNA, using iQ SYBR Green Supermix (Bio-Rad) and an
iCycler Real-Time PCR Detection System (Bio-Rad). PCR mix
contained per sample: 10 ml SYBR Green Supermix, 2 ml
(20 pmol) each primer, 1 ml water and 5 ml DNA. QPCR cycling
protocol was as follows: 3 min initial denaturation at 95uC,
followed by 40 cycles at 95uC for 30 sec, 63uC for 30 sec and 72uC
for 45 sec, and finalized by a melt-curve analysis (55uCt o9 5 uC,
with 0.5uC increments for 10 sec). FOXP2 was used as control for
normalization (as it is known to have no CNV, reference). Copy
number calculations were performed using the delta-delta Ct
method, and the average copy number was set at 2.The results
from qPCR were correlated with those from the MLPA assay
using GraphPad Prism software v5.
Sequencing
The MLPA assay showed inconsistent results across the different
probes used for FCGR3B gene. Therefore, the promoter region of
the FCGR3B gene was sequenced to verify if any kind of genetic
abnormalities, such as previously unreported SNPs or insertion/
deletions (indels), were present within the regions targeted by the
probes. Genomic DNA (25 ng) was amplified and sequenced using
the following primers: FCGR3B_seq_FW (CCT GGA GCC CTG
GAT CCT A) and FCGR3B_seq_RV (CTA AAG GGA CCA
AGC CGA CTA). PCR amplification was performed using a
Promega GoTaq PCR kit (according to the manufacturer’s
standard protocol) and an Applied Biosystems 9700 Thermal
Cycler. The cycling protocol comprised an initial denaturation
step at 94uC for 3 min, followed by 37 cycles at 94uC for 45 sec,
64uC for 45 sec and 72uC for 1 min, followed by a final elongation
step at 72uC for 7 min. PCR products were purified using a
QIAGEN PCR Purification Kit, according to QIAGEN’s manual.
PCR products concentration and purity was determined using a
Nanodrop spectrophotometer system. Sequencing was performed
in an Applied Biosystems’ ABI PRISM 3730 Analyzer and data
was analysed with Chromas 2 (Technelysium).
Statistical analysis
The x2 test with 2 degrees of freedom (Epi Info v6, CDC,
Atlanta, Georgia, USA) was used to compare the relation between
genotypes and CNV and RA susceptibility. R statistical software
(version 2.5.0) was used to cluster intensity ratios and validate the
cut-offs of the discrete copy number genotypes. P-values were
considered statistically significant if ,0.05.
Results
FCGR3B copy number quantification and association with
rheumatoid arthritis
The copy numbers of the FCGR3B gene were determined by
MLPA using three independent probes. MLPA probe locations,
targeting paralogous sequence variations between FCGR3A and
FCGR3B, are depicted in Figure 1. Peak heights were normalized
Figure 2. Copy number of FCGR3B gene in RA patients versus healthy controls. The normalized MLPA ratios measured with FCGR3B#1,
FCGR3B#2 and FCGR3B#3 probe-sets are plotted for RA patients and healthy controls. Three genes EXT1, CREBBP and EP300 were used as reference
for normalization (2 copies without CNV) and are shown here for all individuals. The clusters reflecting the copy numbers are illustrated by grey ovals.
FCGR3B#1 and FCGR3B#2 showed clear clusters and copy numbers could be assigned, while FCGR3B#3 showed no CNV.
doi:10.1371/journal.pone.0013173.g002
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from known autosomal dominant disease genes, which would not
be deleted or duplicated without an obvious phenotype. The
normalized MLPA ratios were plotted to visualize the distinct copy
numbers clusters (Figure 2). As expected, the reference genes
showed no evidence of CNV. Surprisingly, the CNV frequency
considerably differed between the three FCGR3B probes analyzed.
While FCGR3B#1 and FCGR3B#2 probes revealed clear
clustering indicating gene copies ranging from 0 to 5, the third
probe FCGR3B#3 showed little evidence of CNV. The
frequencies of copy number variations are shown in (Table 2).
FCGR3B#1 probe measured copy numbers ranging from 0 to
3 copies. One copy was the most frequent copy number, occurring
in 44.3% of the controls and 41.9% of the RA patients.
Furthermore, the FCGR3B#1 probe reported homozygous
deletion (0 copies) in 16.9% of healthy controls versus 12.9%
RA patients, and gene amplification (3 copies) in 0.4% of healthy
controls versus 2.4% of RA patients (OR=6.23, P=0.05). In
contrast, FCGR3B#2 probe showed that most individuals
(.80%) contained 2 copies of FCGR3B. High copy number
(mainly 3 copies and few individuals with 4–5 copies) was present
in 9.4% of controls and 11.7% of RA patients OR=1.27,
95%CI=0.74–2.2, P=0.36. Conversely, low copy number (1
copy) was present in 6.7% of the controls compared to 6.0% of RA
patients OR=0.89, 95%CI=0.45–1.76, P=0.71.
To investigate the reason why the three FCGR3B probes,
located within 500 bp from each other, produced such different
results we sequenced the promoter region of FCGR3B and
measured the number of gene copies by quantitative PCR (qPCR).
Sequencing of the FCGR3B promoter region
A 843 base-pair segment of the FCGR3B promoter encompass-
ing the binding sites for the three MLPA probes was amplified and
sequenced, to control for eventual unreported genomic variations
that could affect probe ligation. Sequencing results revealed the
presence of a 2 nucleotides insertion/deletion (indel) polymor-
phism, located exactly at the ligation site for the probe
FCGR3B#1 (Figures 3A). This polymorphism consisted of the
deletion of the A nucleotide at position 256 upstream of the
transcription starting site, followed by TG insertion. This FCGR3B
indel polymorphism has not been previously reported in the
literature or public SNP databases, and will be referred throughout
the manuscript as -256A.TG indel. The TG insertion prevents
the ligation of the two FCGR3B#1 half-probes on the target
sequence and subsequently, the absence of signal is misread as a
lowered copy number of the FCGR3B gene. It is important to note
that the -256A.TG indel is not a rare polymorphism, judging
from the high frequency of low copy numbers measured with
the FCGR3B#1 probe. Finally, these results showed that the
FCGR3B#1 probe simultaneously measures CNV and the
-256A.TG indel genotype of the FCGR3B gene, thus explaining
the discordant results between that probe and the FCGR3B#2.
FCGR3B copy number determination by quantitative PCR
The sequencing results explain the discrepancy between the
FCGR3B#1 probe and FCGR3B#2 probe but not with
FCGR3B#3. Quantitative PCR was chosen as an independent
method to measure the copy number of FCGR3B and was
performed on 24 samples (Figure 3B). The results from qPCR
were correlated with those from probe FCGR3B#2, with a
Pearson R of 0.65 (P=0.0009). In contrast, the copy numbers
measured with FCGR3B#3 probe did not correlate with those
from qPCR Pearson R=0.35, P=0.1. In conclusion,
FCGR3B#2 showed to be a reliable probe for CNV quantifica-
tion, whereas FCGR3B#3 appeared to be not reliable for this
purpose.
Combining the data from MLPA and sequencing of
FCGR3B
The data described above indicate the presence of an additional
genetic variant in the FCGR3B promoter. The finding of the -
256A.TG indel raised the question whether this novel variant
was associated with susceptibility to RA. This genetic analysis was
complicated by the presence of CNV next to the -256A.TG
polymorphism in the FCGR3B gene. Therefore, we combined the
MLPA data from FCGR3B#2 probe (providing information
about CNV) with the data from FCGR3B#1 probe (information
about CNV and -256A.TG indel genotype). The MLPA
normalized ratios were plotted in Figure 4A for the RA patients
and Figure 4B for the healthy controls.
The presence of the -256A.TG indel disrupts the binding and
ligation of the FCGR3B#1 MLPA probe. Therefore, this probe
only measures the number of copies of the wild-type allele (without
the indel). On the other hand, the FCGR3B#2 probe measures
the total number of copies of the FCGR3B gene. The difference
between the signals of FCGR3B#2 and FCGR3B#1 probes
equals the number of -256A.TG alleles. For example, an
individual showing 2 copies with FCGR3B#2 and 2 copies with
FCGR3B#1 has 2 copies of the wild-type (WT) FCGR3B gene; but
an individual showing 2 copies with FCGR3B#2 but only 1 copy
with FCGR3B#1 has one WT allele and one -256A.TG allele.
Obviously, the copy number obtained with probe FCGR3B#1
can never be higher than that determined with FCGR3B#2
Table 2. Copy number of FCGR3B determined with three
independent MLPA probes.
MLPA
Probe RA Controls
Low/high
CN vs rest
Count % Count % P
OR
(95% CI)
FCGR3B
#1
0 Gene
Copies
54 12.9% 43 16.9% 0.104 0.77
(0.55–1.07)
1 Gene
Copy
175 41.9% 113 44.3%
2 Gene
Copies
179 42.8% 98 38.4%
3 Gene
Copies
10 2.4% 1 0.4% 0.047 6.23
(0.82–131)
FCGR3B
#2
Low CN 25 6.0% 17 6.7% 0.712 0.89
(0.45–1.76)
2 Gene
Copies
344 82.3% 213 83.9%
High CN 49 11.7% 24 9.4% 0.359 1.27
(0.74–2.2)
FCGR3B
#3
Low CN 3 0.7% 0 0.0% ND ND
2 Gene
Copies
416 99.3% 252 98.8%
High CN 0 0.0% 3 1.2% ND ND
Mantel-Haenszel p-values were calculated. (ND) p-values and OR were not
determined because the number of events was too low.
doi:10.1371/journal.pone.0013173.t002
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analysis as they measured 2–3 copies with FCGR3B#1 probe and
1–2 copies with probe FCGR3B#2, respectively, which represents
a technical error rate ,1% (see grey areas of the graphs on
Figure 4).
Table 3 shows the frequencies of the FCGR3B polymorphisms,
as detected by the 2 probes and stratified for the presence (mutant
type: MT) or absence (wild-type: WT) of the -256A.TG indel.
The WT.MT genotype was more frequent in RA patients than
healthy controls (48% versus 40.8%, P=0.1). Conversely, the
WT,MT genotype was more frequent in healthy controls than
RA patients (20.4% versus 15.4%). In other words, RA patients
tended to have less copies of the ‘‘mutated’’ -256A.TG FCGR3B
allele (35.9 versus 40.7%, P=0.08), although this trend did not
reach statistic significance. Stratification of the RA patients for the
presence of ACPA antibodies did not change the results (data not
shown).
Discussion
DNA segments in sizes ranging from kilobases to megabases can
vary in copy number between different individuals [18,20,25].
These CNVs are an important source of genetic variation, which
are not only responsible for population diversity but may also
contribute to the inter-individual variability in disease susceptibil-
ity. A recent study of gene expression variation as a model of
complex phenotype measured the fraction of gene expression
‘traits’ that could be associated with either single nucleotide
polymorphisms (SNPs) or CNVs [44]. In this study, SNP
genotypes and CNV measurements were associated with 83%
and 18%, respectively, of those gene expression traits for which
statistically significant associations were found. This may still
underestimate the role of CNVs, given the higher frequency of
SNPs as well as the greater completeness and accuracy with which
SNPs can be queried at present [43,45].
Curiously, there appears to be an enrichment of CNVs in
genomic regions encoding immune response genes and secreted
molecules [18,46]. This finding suggests that CNVs affecting
expression of immunity genes may play a functional role in
infectious and autoimmune diseases, in particular. Supporting this
hypothesis are previous publications describing association of
CNVs in FCGR3B and complement component 4 (C4A/C4B) with
systemic lupus erythematosus (SLE), FCGR2C with idiopathic
thrombocytopenic purpura (ITP), defensin beta (DEFB) with
psoriasis and Crohn disease, CCL3L1 with HIV-AIDS infection,
SLE, rheumatoid arthritis (RA) and type 1 diabetes (reviewed in
[47]). On the other hand, two recent genome wide association
studies (GWAS) of CNVs suggest that this type of variation is
unlikely to identify novel genetic loci associating with common
human diseases [48,49]. This conclusion was based on two key
Figure 3. Validation of the FCGR3B MLPA probes. A. Example of the sequencing results for an individual homozygous for the novel FCGR3B
-256A.TG indel at the ligation site of MLPA probe FCGR3B#1. B. Validation of the results of probe FCGR3B#2 (but not FCGR3B#3) by quantitative
RT-PCR.
doi:10.1371/journal.pone.0013173.g003
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MAF.10%) are well-tagged by SNPs (r2.0.8) and have already
been indirectly screened in existing SNP GWAS studies; (ii) the
number of confirmed disease associating loci in the CNV GWAS
was much smaller than the number of loci identified in SNP
GWAS, and consisted of already known associations (HLA for RA,
T1D and Crohn’s disease; TSPAN8 for T2D; IRGM for Crohn’s
disease) [47]. However, rare CNVs (MAF,10%) are poorly
tagged by SNPs and may have been missed in SNP-based GWAS,
which encourages further CNV genotyping studies. Additionally,
regions that have increased recombination, e.g. duplicons that
include the FCGR3B gene, are unlikely to be tagged well.
In the current study we investigated the association of CNVs of
the FCGRs genes with RA susceptibility. Several methods can be
Figure 4. FCGR3B MLPA probes FCGR3B#1 versus FCGR33B#2. MLPA normalized ratios were cross-plot in RA patients (A) and healthy
controls (B). Boxes delineate the clusters and the number of individuals within each cluster is shown on the upper left. WT: wild-type allele of FCGR3B
(without the -256A.TG indel). MT: mutant-type (-256A.TG indel) allele of the FCGR3B gene.
doi:10.1371/journal.pone.0013173.g004
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tion, PCR, sequencing and genome-wide array based approaches
[50]. In the present study we have chosen for multiplex ligation-
dependent probe amplification (MLPA), a simple high-throughput
method, which has the advantages of consuming relatively low
amounts of genomic DNA and a cost-effective multiplexing
potential. MLPA utilizes a ligation step to join two separate
oligonucleotide half-probes after hybridization [41]. This provides
increased sensitivity to distinguish highly homologous sequences,
by designing the half-probes such that a difference in sequence is
located under or near the ligation site [51]. However, unsuspected
sequence changes at or near the ligation site may lead to erroneous
interpretations, as these disturb the ligation reaction and may
result in the absence of signal, which is consequently misunder-
stood as a deletion [52,53]. This limitation is not restricted to the
MLPA assay but to most primer/probe based assays. Thus a
deletion detected with a single probe set needs to be confirmed
with another assay, for example with quantitative PCR.
The FCGR locus on chromosome 1q23 originated from
segmental duplication and cross-over events, which resulted in
high homology between the five low affinity FCGR genes [4]. This
high homology, together with the presence of multiple (unchar-
acterized) SNPs, makes it extremely difficult to distinguish between
these genes and to design probes for genotyping assays, which may
lead to erroneous interpretations [54]. During the preparation of
this manuscript, three independent studies report on the FCGR3B
gene copy number in association with the risk of developing
autoimmune diseases, including RA [48,55,56]. The results of
these studies are conflicting: while McKinney et al. observed a
significant association of low FCGR3B gene copy number (CN,2)
with RA, that was not the case in the studies by Mantani et al. and
the CNV GWAS from the Wellcome Trust Consortion [48,55,56].
These conflicting reports further strengthen the notion that, due to
a high degree of homology, CNV in this FCGR locus is difficult to
measure and results are sometimes difficult to interpret. It could be
argued that, having a smaller sample size, our present study (518
RA patients and 304 healthy controls) and that of Mantani et al.
(158 cases and 409 controls) had limited power to detect a
significant association, compared to the study of McKinney et al.
(in total, 1661 cases and 1374 controls from New Zeeland, the
Netherlands and the UK) [55,56]. Nonetheless, our present study
had a power of 90% to detect an OR=2.01 and a power of 70%
for OR=1.67, which are the effect sizes reported by McKinney
et al. in the ‘‘Dutch RA’’ and ‘‘Combined RA’’ populations,
respectively [55]. Also, it should be noticed that the OR we
detected (0.89, confidence interval 0.45–1.76) is not in the same
direction as the effect reported by McKinney et al. Finally, the
study from the Welcome Trust Case Control Consortium was the
largest CNV study reported to date, including 2000 RA cases and
3000 controls [48]. Therefore, we believe that the lack of
association cannot merely be explained by an insufficient statistical
power of these studies. Nevertheless, it remains difficult to explain
why two Dutch cohorts (ours and that of McKinney et al.) yield
different results. We feel that the most likely explanation is found
in the different methods and probes used in each study to target
this complex region. The quantitative real-time PCR assay used by
Mantani et al. to measure FCGR3B CNV targeted the same
sequence as our FCGR3B#2 probe and yielded similar results
[56]. McKinney et al. also used a quantitative PCR based
technique, but the assay used may not be specific for FCGR3B,
due to the presence of FCGR3A SNPs (rs57263253 and
rs60966737) in one of the TaqMan primers [55]. Since the
frequency of these potential SNPs is unknown, it is difficult to
ascertain the possible effect they could have on the CNV
measurement. Finally, the GWAS case control study from the
Wellcome Trust Consortion used a comparative genomic
hybridization (CGH) microarray approach, but the probe used
in this region was not specific for the FCGR3B and could not
distinguish from the FCGR3A gene [48]. Thus, it is possible that
the disparate results between the different studies are due to
technical issues that hamper accurate CNV measurement in this
locus. Additionally, we identified a novel insertion/deletion
polymorphism (-256A.TG) in the promoter region of the
FCGR3B gene. The finding of FCGR CNVs and novel
polymorphisms adds an extra level of complexity to this already
intricate region. To illustrate this problem we describe here the
example of our three FCGR3B probes, which all showed different
copy number results in the MLPA assay. Using the human
reference FCGR sequences (NCBI Build 36.1) and SNP
information from dbSNP built 126, these probes were designed
to be specific for FCGR3B gene, avoiding SNPs in FCGR3A that
would make it ‘‘look’’ like FCGR3B and, obviously, in the absence
of SNPs at the probe ligation site. However, failure of
FCGR3B#1 probe in 15% of the individuals, which seemed too
high a frequency for deletion, prompted us to sequence the
promoter region of FCGR3B gene in 24 individuals. This lead to
the discovery of the -256A.TG indel, a novel polymorphisms at
the ligation site of the FCGR3B#1 probe. The data from
FCGR3B#3 probe could not be explained by sequencing, as this
probe lacked unreported SNPs or indels. Therefore, real time
PCR was used quantify FCGR3B copy number in 24 individuals,
which validated the data from FCGR3B#2 probe and excluded
the results from FCGR3B#3. The strength of our study resides in
the combination of these three techniques: MLPA, real-time PCR
and sequencing, reaching a dept that cannot be achieved by large-
scale GWAS studies.
A problem of another kind for genetic studies in copy number
variable regions is caused by the presence of CNVs resulting in low
SNP call rates, so that validated SNPs tend to occur with low
densities in regions harboring CNVs. This is due to the fact that
deletions and amplifications can lead to a skewing in the pattern of
marker genotypes [20,37]. The subsequent Hardy-Weinberg
disequilibrium limits the ability of the genome-wide SNP
association studies to detect disease associated SNPs in regions
with CNV [45]. Additionally the presence of CNVs may blur the
association of the studied SNPs with disease susceptibility [37].
Table 3. FCGR3B gene stratified for the -256A.TG indel
polymorphism.
RA Controls
Count (%) Count (%)
WT.MT 197 (48%) 102 (40.8%)
WT=MT 150 (36.6%) 97 (38.8%)
WT,MT 63 (15.4%) 51 (20.4%)
MT allele 306 (35.9%) 207 (40.7%)
WT allele 546 (64.1%) 302 (59.3%)
OR (95% CI) 0.82 (0.65–1.03)
Allelic P-Value 0.08
Genotypic P-value 0.12
WT = Wild-type FCGR3B allele (adenine at position 2256 of FCGR3B gene).
MT = Mutant type of the FCGR3B gene (deletion of the adenine nucleotide at
position 2256, followed by the insertion of thymine/guanine dinucleotide).
doi:10.1371/journal.pone.0013173.t003
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thought of as allele sizes, is not yet routinely possible; most
technologies are able to quantify only the total phenotype or the
sum of all alleles detected. The accurate assignment of the copy
number (integer count) in an individual will present new
challenges to assays, and proposals to use quantitative SNP
genotypes to infer CNVs will require more-refined calling
algorithms [20,57].
In conclusion, CNV of the FCGR3B gene was detected in the
Dutch population but did not associate with the risk of developing
RA. However, a trend of association was also found for a newly
identified polymorphism in the promoter region of this FCGR3B
gene, the -256A.TG indel. Larger studies will be needed to
convincingly validate these findings. Finally, the conflicting results
found for the different FCGR3B probes illustrate the complexity of
this very homologous region and the urgent need for a thorough
characterization of this locus. Only so will future genetic studies of
these crucial immunity genes yield consistent and reliable results.
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